1
|
Gogoi U, Gogoi N, Rajkhowa S, Khan SA, Daffa Alla Omer Hajedris N, Al-Hoshani N, Al-Shouli ST, Das A. Expanding the therapeutic arsenal against cancer: a computational investigation of hybrid xanthone derivatives as selective Topoisomerase 2α ATPase inhibitors. J Biomol Struct Dyn 2023:1-30. [PMID: 37975405 DOI: 10.1080/07391102.2023.2280723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 11/01/2023] [Indexed: 11/19/2023]
Abstract
The DNA topoisomerase II (topo II) enzyme plays an important role in the replication, recombination, and repair of DNA. Despite their widespread applications in cancer therapy, new, selective, and potent topo II inhibitors with better pharmaceutical profiles are needed to handle drug resistance and severe adverse effects. In this respect, an array of 36 new anticancer compounds was designed based on a Xanthone core tethered to multifunctional Pyridine-amines and Imidazole scaffold via alkyl chain linkers. An integrated in silico approach was used to understand the structural basis and mechanism of inhibition of the hybrid xanthone derivatives. In this study, we established an initial virtual screening workflow based on pharmacophore mapping, docking, and cancer target association to validate the target selection process. Next, a simulation-based docking was conducted along with pharmacokinetic analysis to filter out the five best compounds (7, 10, 25, 27, and 30) having binding energies within the range of -60.45 to -40.97 kcal/mol. The screened compounds were further subjected to molecular dynamics simulation for 200 ns followed by MM-GBSA and ligand properties analysis to assess the stability and binding affinity to hTOP2α. The top-ranking hits 3,7-bis(3-(2-aminopyridin-3-ylhydroxy)propoxy)-1-hydroxy-9H-xanthen-9-one (ligand 7) and 3,8-bis(3-(2-aminopyridin-3-ylhydroxy)propoxy)-1-hydroxy-9H-xanthen-9-one (ligand 25) were found to have no toxicity, optimum pharmacokinetic and, DFT properties and stable intermolecular interactions with the active site of hTopo IIα protein. In conclusion, further in vitro and in vivo experimental validation of the identified lead molecules is warranted for the discovery of new human Topoisomerase 2 alpha inhibitors.Communicated by Ramaswamy H. Sarma.
Collapse
Affiliation(s)
- Urvashee Gogoi
- Department of Pharmaceutical Sciences, Faculty of Science & Engineering, Dibrugarh University, Dibrugarh, Assam, India
| | - Neelutpal Gogoi
- Department of Pharmaceutical Sciences, Faculty of Science & Engineering, Dibrugarh University, Dibrugarh, Assam, India
| | - Sanchaita Rajkhowa
- Centre for Biotechnology and Bioinformatics, Dibrugarh University, Dibrugarh, Assam, India
| | - Shah Alam Khan
- College of Pharmacy, National University of Science and Technology, Muscat, Oman
| | - Nisreen Daffa Alla Omer Hajedris
- College of Medicine, Basic Medical Department, Almaarefa University, Riyadh, Saudi Arabia
- Faculty of Medicine, Department of Physiology, Khartoum University, Khartoum, Sudan
| | - Nawal Al-Hoshani
- Department of Biology, College of Science, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia
| | - Samia T Al-Shouli
- Immunology Unit, Pathology department, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
| | - Aparoop Das
- Department of Pharmaceutical Sciences, Faculty of Science & Engineering, Dibrugarh University, Dibrugarh, Assam, India
| |
Collapse
|